BEIKE BIOTECHNOLOGY CO. LTD.

Company Overview

Beike Biotechnology Co. Ltd. is a biotechnology company focused on adult stem cell technologies for treating incurable diseases. The company was incorporated in July 2005 by Xiang Hu. Beike’s therapeutic areas include Alzheimer’s disease, Ataxia, Friedreich’s disease, autism, multiple sclerosis (MS), muscular dystrophy, Duchenne’s disease and spinal muscular atrophy. Shenzhen Beike has partnership with Tsinghua University.

The company currently produces a full line of stem cell products derived from umbilical cord, cord blood and bone marrow stem cells. Beike’s proprietary processing and quality assurance technologies prepare the cells for use in treating various serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury and optic nerve damage.

Beike’s stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government-appointed blood banks and Beike’s specialized laboratories. The stem cells are then banked in state-of-the-art facilities and only utilized in partnership with the best hospitals and physicians.

In July 2015, Beike, together with leading Chinese hospitals and universities, published new research utilizing mesenchymal stem cells derived from Wharton’s Jelly as a safe and effective treatment for acute myocardial infarction, more commonly known as heart attack. This double-blind, randomized controlled trial used intracoronary infusion as a delivery method for the adult stem cells produced by Beike Biotechnology. Wharton’s Jelly is derived from umbilical cord tissue, the main source of Beike’s mesenchymal stem cell products.

The use of adult stem cells is limited by the quality and quantity of host stem cells. It has been demonstrated that Wharton’s jelly-derived mesenchymal stem cells (WJMSCs), a primitive stromal population, could integrate into ischemic cardiac tissues and significantly improve heart function. In this randomized, controlled trial, the aim was to assess the safety and efficacy of intracoronary WJMSCs in patients with ST-elevation acute myocardial infarction (AMI). Results indicated that intracoronary infusion of WJMSCs is safe and effective in patients with AMI, providing clinically relevant therapy within a favorable time window. The study encouraged additional clinical trials to determine whether umbilical cord-derived mesenchymal stem cells may serve as novel alternatives to bone marrow stem cells for cardiac stem cell-based therapy.

Company's Business Segments

• Technology : Umbilical Cord Blood-Derived Stem Cells (UCBSC), Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC), Major Histocompatibility Antigen Receptor (MAR), Tri-functional T cell Engager (TriTE), MAR-T.
• Pipeline : Timmune, ALT-803.